A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved hard to treat. First approved by the FDA in 2017, CAR T-cell therapy has the potential to cure your cancer. Here ...

I have had lymphoma ... CURE blogs helps me process all that I’m going through and I am starting to convince myself that I should take my doctor’s advice. Maybe now is the right time to stop this BTK ...

which uses a small amount of radioactive dye to find areas of cancer There are a few subtypes of DLBCL. Each one has a different treatment and outcome. Primary mediastinal B-cell lymphoma starts ...

Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.

F. Hoffmann-La Roche Ltd (Roche) has a rich history of antibody therapies to treat cancers (malignancies) that affect B cells (a type of white blood cell), including non-Hodgkin lymphoma and ...

Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma ... for these patients (around 60% will be cured), still approximately 30—40% of ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.